Correlation Between Marizyme and Oncology Pharma

Can any of the company-specific risk be diversified away by investing in both Marizyme and Oncology Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Marizyme and Oncology Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Marizyme and Oncology Pharma, you can compare the effects of market volatilities on Marizyme and Oncology Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Marizyme with a short position of Oncology Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Marizyme and Oncology Pharma.

Diversification Opportunities for Marizyme and Oncology Pharma

0.17

Correlation Coefficient

Marizyme  Oncology Pharma

Average diversification

The 3 months correlation between Marizyme and Oncology is 0.17. Overlapping area represents the amount of risk that can be diversified away by holding Marizyme and Oncology Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncology Pharma and Marizyme is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Marizyme are associated (or correlated) with Oncology Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncology Pharma has no effect on the direction of Marizyme i.e., Marizyme and Oncology Pharma go up and down completely randomly.

Pair Corralation between Marizyme and Oncology Pharma

Given the investment horizon of 90 days Marizyme is expected to generate 65.25 times less return on investment than Oncology Pharma. But when comparing it to its historical volatility, Marizyme is 18.24 times less risky than Oncology Pharma. It trades about 0.1 of its potential returns per unit of risk. Oncology Pharma is currently generating about 0.35 of returns per unit of risk over similar time horizon. If you would invest  0.02  in Oncology Pharma on September 5, 2024 and sell it today you would lose (0.01) from holding Oncology Pharma or give up 50.0% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	89.06%
Values	Daily Returns

Marizyme  vs.  Oncology Pharma

Marizyme

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Marizyme are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of very inconsistent basic indicators, Marizyme displayed solid returns over the last few months and may actually be approaching a breakup point.

Oncology Pharma

Risk-Adjusted Performance

27 of 100

Strong

Compared to the overall equity markets, risk-adjusted returns on investments in Oncology Pharma are ranked lower than 27 (%) of all global equities and portfolios over the last 90 days. Despite fairly uncertain basic indicators, Oncology Pharma demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Marizyme and Oncology Pharma

The main advantage of trading using opposite Marizyme and Oncology Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Marizyme position performs unexpectedly, Oncology Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncology Pharma will offset losses from the drop in Oncology Pharma's long position.

The idea behind Marizyme and Oncology Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.